Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest ViroPharma Incorporated Stories

2012-02-14 15:00:00

EXTON, Pa., Feb. 14, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Leerink Swann 2012 Global Healthcare Conference at 3:00 P.M. ET on Thursday, February 16, 2012. The conference is being held at the Waldorf Astoria in New York City. Mr. Rowland also will present at the Cowen and Company 32nd Annual Healthcare Conference at 11:20 A.M. ET on Wednesday,...

2012-02-07 06:30:00

EXTON, Pa., Feb. 7, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the U.S Food and Drug Administration (FDA) issued a complete response letter regarding Cinryze® (C1 Esterase Inhibitor [Human]) industrial scale manufacturing expansion activities. Specifically, the FDA has three comments related to a portion of the cleaning validation for industrial scale manufacturing, of which only one requires additional unplanned activity. The company expects...

2012-01-13 06:30:00

EXTON, Pa., Jan. 13, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that Health Canada has granted the company Priority Review status for its New Drug Submission (NDS) for Cinryze((TM)) (C1 inhibitor [human]). Priority Review allows for an expedited review of critical new drugs faster than a standard review. ViroPharma has 60 days from the time of issuance of this acceptance letter to submit its full submission to Health Canada; once submitted,...

2012-01-05 15:30:00

EXTON, Pa., Jan. 5, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will provide an overview of the company's business during the 30th Annual J.P. Morgan Healthcare Conference. The presentation will be webcast live at 7:30 P.M. ET (4:30 P.M. PT) on Tuesday, January 10, 2012 and may be accessed via the company's website at www.viropharma.com. The conference is being...

2012-01-03 15:30:00

EXTON, Pa., Jan. 3, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the appointment of Julie H. McHugh to its board of directors. Ms. McHugh brings a wealth of pharmaceutical and health care industry experience and leadership to ViroPharma's Board of Directors. She is currently the chief operating officer of Endo Pharmaceuticals, a U.S.-based, specialty healthcare solutions company. Prior to joining Endo, Ms. McHugh was chief executive officer of...

2011-12-22 17:00:00

EXTON, Pa. and SAN DIEGO, Dec. 22, 2011 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus. ViroPharma has paid an initial $7.5 million, and has agreed to provide Meritage up to an...

2011-12-14 13:30:00

EXTON, Pa., Dec. 14, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the modernization of labeling for Vancocin® (vancomycin hydrochloride, USP) Capsules made effective through the U.S. Food and Drug Administration's (FDA) approval of a supplemental new drug application (sNDA). The company also provided updates on ViroPharma's ongoing citizen petition and litigation with the FDA regarding Vancocin. Vancocin Labeling...

2011-12-06 07:00:00

EXTON, Pa., Dec. 6, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics (Nasdaq: HALO) today announced positive top line data from ViroPharma's open-label, multiple dose Phase 2 clinical trial designed to evaluate the safety, pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze® (C1 esterase inhibitor [human)] in combination with Halozyme's Enhanze(TM) technology, a proprietary drug delivery platform...

2011-12-05 09:30:00

EXTON, Pa., Dec. 5, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Robert Doody, assistant director of investor relations of ViroPharma, will present at the 2011 Deutsche Bank BioFEST Conference at 8:35 A.M. ET on Tuesday, December 6, 2011. The conference is being held at the Four Seasons Hotel in Boston. Charles Rowland, vice president and chief financial officer, of ViroPharma, will present at the Oppenheimer 22(nd) Annual Healthcare Conference at...

2011-11-15 07:00:00

EXTON, Pa., Nov. 15, 2011 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that it completed its acquisition of DuoCort Pharma AB, a private company based in Helsingborg, Sweden focused on improving glucocorticoid replacement therapy. The acquisition of Duocort Pharma AB further expands ViroPharma's orphan disease commercial product pipeline. ViroPharma has paid an upfront closing cost of 220 million Swedish kroner (SEK) or $33.6 million in US dollars (USD)....